Hermann Mucke (bioscientist)
Hermann A. M. Mucke (born 4 September 1955) is an Austrian bioscientist with a peer-review publishing record in the fields of molecular biology, neuropsychiatry, cardiology and ophthalmology, mostly from the perspective of drug development. He is also a management consultant and entrepreneur working and publishing in biopharmaceutical strategic knowledge management, intellectual property management, and life science technology assessment.
Academic career
Hermann Mucke attended the
Industry research executive
After leaving the university Mucke became executive director of research and development at an Austrian pharmaceutical company. He developed an indirect
In 1994 Mucke developed a new research focus in neuropsychiatry, initially with a focus on
Soon thereafter he began to cooperate with various pharmaceutical intelligence providers and publishers in the United States and the United Kingdom, both as an author and as a contributing editor.Industry advisor and publisher
When in 2000 Mucke resigned his executive function in the pharmaceutical industry to set up his own consulting enterprise, the financial newspaper
By 2009 Hermann Mucke had authored or co-authored about 50 peer reviewed original research papers and invited reviews, in addition to dozens of drug evaluations. He is also a coinventor on several patent families which concern themselves with the pharmacotherapy of alcohol abuse,[20][21] nicotine dependence,[22] and depression.[23]
Hermann Mucke is Patent Editor at the Thomson Reuters journal, Current Opinion in Investigational Drugs [24] and an advisor to the Antiviral Spot of Excellence Vienna (ASPEX).[25] He is frequently interviewed by media covering the pharmaceutical industry, mostly on issues concerning the streamlining of drug development through optimization of clinical trials,[26][27] new approaches to the clinical trial process,[28] or medical imaging.[29]
References
- PMID 6244191
- ISBN 90-247-2946-7
- ^ Janssen I, Mucke H, Löffelhardt W and Bohnert HJ. The Central Part of the Cyanelle rDNA Unit of Cyanophora paradoxa: Sequence Comparison with Chloroplasts and Cyanobacteria. Plant Mol. Biol. 9, 479-484 (1987)
- ^ Sullivan MT, Mucke H, Kadey SD, Fang CT, Williams AE. Evaluation of an indirect immunofluorescence assay for the confirmation of HIV-1 antibody in U.S. blood donor sera. J Clin Microbiol 30(9), 2509-2510 (1992) PDF
- ^ List of FDA-approved HIV and hepatitis tests
- PMID 1395126
- PMID 9354429
- PMID 16923577
- ^ Mucke HAM, Czollner K. SPH-1286, a novel potent inhibitor of brain acetylcholinesterase, can prevent amnesia after acute moderate hypoxia-hypercarbia. J Cerebral Blood Flow and Metabolism 19(Suppl. 1), p. S19 (1999)
- ^ WO/1997/026887 Use of galanthamine in the preparation of novel drugs. Published July 31, 1997 Link to PCT document
- ^ WO/2000/032199. Use of galantamine and galantamine derivatives in the case of acute functional brain damage. Published June 8, 2000 Linkt to PCT document
- ^ Pridun C; Menschen in Bewegung. wirtschaftsblatt online archive article Archived 2011-07-26 at the Wayback Machine, April 14, 2000. Accessed: 2009-06-15. Archived
- ^ Mucke HAM, Mucke P, Mucke E. International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics. Clin Ophthalmology 3: 103–109 (2009) Open Access paper Archived
- PMID 17187313
- PMID 14582447
- PMID 17002256
- PMID 18729002
- ^ Mucke HAM. Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity? Clinical Medicine: Therapeutics 1: 111-121 (2009) Open Access paper Archived
- PMID 19517317
- ^ WO/2002/102388 Active ingredient combination of e.g. galantamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism. Published December 27, 2002. Link to PCT document
- ^ WO/2004/014393. Medicament and method for reducing alcohol and/or tobacco consumption. Published Feb. 19, 2004. Link to PCT document
- ^ WO/2003/007966. Active substance combination for medicamentous therapy of nicotine dependency. Published January 30, 2003. Link to PCT document
- ^ WO/2003/053445. Use of desoxypeganine for treating clinical depression. Published July 3, 2002. Link to PCT document
- ^ COID journal website
- ^ "ASPEX website". Archived from the original on 2009-06-15. Retrieved 2009-06-15.
- ^ Borman S: Improving Efficiency. Chemical & Engineering News Special Issue published June 19, 2006. Vol 84(25):56-78 Link to article Archived
- ^ Davies K.: Putting the IT in Clinical Trials. BioIT World Vol. 5 Issue 3, p14. April 14, 2006. Link to article Archived
- ^ May M: Exploratory INDs: A Trial Before the Trials. BioIT World Dec. 17, 2007. Link to article Archived
- ^ Ward J: From Mice to Men: Is Imaging the Magic Pill for Faster Drug Development? ADVANCE for Imaging & Radiation Oncology. February 23, 2005. Link to article Archived 2011-07-07 at the Wayback Machine Archived
External links
- Peer-reviewed papers by Hermann A.M. Mucke in PubMed Dynamic query
- Papers by Hermann A. M. Mucke in Google Scholar Dynamic query
- Literature-based profile for Hermann A.M. Mucke at BiomedExperts Dynamic query